Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Pembrolizumab and Chemotherapy or Surveillance in Early Triple Negative breAst Cancer With High Stromal Tumor-infiltrating Lymphocytes (TILs) Score

NCT06078384 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06078384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06078384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Pembrolizumab and Chemotherapy or Surveillance in Early Triple Negative breAst Cancer With High Stromal Tumor-infiltrating Lymphocytes (TILs) Score
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
December 27, 2024
Completion date
January 1, 2032
Enrollment
354 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer